Sun Pharma aims to gain market share in all verticals amid COVID-19 pandemic
The drug major, which has presence in around 150 countries, caters to various various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ashok BhutaDesignation :- Any Other SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed certificate dated 10th July, 2020 for the quarter ended 30th June, 2020 received from M/s. Link Intime (India) Private Limited, Registrar & Share Transfer Agent of the Company. This is for your information and record. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed Annual Secretarial Compliance Report for the financial year 2019-20 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 07, 2020 for Shanghvi Finance Pvt Ltd Sun Pharma shuts Dadra plant after 17 employees test positive for Covid-19
Sun Pharmaceutical Industries Ltd has temporarily suspended operations at its second largest facility at Dadra in the Union Territory of Dadra & N Sun Pharma to launch its first innovative product for psoriasis in Japan
Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Undertaking For Non-Applicability Of Large Corporate Criteria
Please find enclosed Undertaking for Non-applicability of Large Corporate Criteria SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to Ilumya approval in Japan, which we shall be releasing after sending this letter to you. This is for your information and record. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended March 31, 2020 in the format specified in the relevant accounting standards for annual results. This is for your information and record.